NEWLY-named biotech group Vernalis, created from British Biotech, has scrapped more than half its drug pipeline. It will focus on research and development of its treatments for menstrually associated migraine, cancer pain and Parkinson's disease.
Create a FREE account to continue reading
Registration is a free and easy way to support our journalism.
Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.
Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged in